Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

Conditions:Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Age Range:18 - 65
Start Date:January 2013
End Date:October 2016
Contact:Cristina Cusin, M.D.

Use our guide to learn which trials are right for you!

Randomized, Double-blind Ketamine Augmentation in Chronically Suicidal, Treatment-resistant Major Depression

Ketamine infusions resulted in an acute reduction in global depression scores and in
severity of suicidal ideation. The investigators therefore plan to investigate the
feasibility and efficacy of repeated intravenous administration of ketamine in severely
depressed, treatment resistant patients. The results of the study could lead to development
of new strategies for treating depression.

Inclusion Criteria:

- Outpatient with sever treatment resistant depression

- Currently depressed

- Currently under regular psychiatric care

- On an aggressive antidepressant regimen, stable for 4 weeks.

Exclusion Criteria:

- No history of other major psychiatric illness, including bipolar

- No history of psychosis

- No history of drug abuse

- No major medical illness or unstable medical problem
We found this trial at
Boston, Massachusetts 02114
Boston, MA
Click here to add this to my saved trials